Liraglutide Improves Glycemic and Blood Pressure Control and Ameliorates Progression of Left Ventricular Hypertrophy in Patients with Type 2 Diabetes Mellitus on Peritoneal Dialysis. (Q51294221)

From Wikidata

Jump to navigation Jump to search

scientific article published on 11 November 2015

Language	Label	Description	Also known as
English	Liraglutide Improves Glycemic and Blood Pressure Control and Ameliorates Progression of Left Ventricular Hypertrophy in Patients with Type 2 Diabetes Mellitus on Peritoneal Dialysis.	scientific article published on 11 November 2015

Statements

scholarly article

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/26556397

Liraglutide Improves Glycemic and Blood Pressure Control and Ameliorates Progression of Left Ventricular Hypertrophy in Patients with Type 2 Diabetes Mellitus on Peritoneal Dialysis. (English)

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/26556397

type 2 diabetes

1 reference

based on heuristic

inferred from title

left ventricular hypertrophy

1 reference

based on heuristic

inferred from title

author name string

Takeyuki Hiramatsu

1

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/26556397

Akiko Ozeki

2

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/26556397

Kazuki Asai

3

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/26556397

Marie Saka

4

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/26556397

Akinori Hobo

5

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/26556397

Shinji Furuta

6

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/26556397

publication date

11 November 2015

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/26556397

Therapeutic Apheresis and Dialysis

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/26556397

19

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/26556397

598-605

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/26556397

6

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/26556397

Cardiovascular biology of the incretin system

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12319

21 January 2018

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12319

21 January 2018

Glucagon-like peptide-1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: Results of a 52-week, randomized, multicenter trial

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12319

21 January 2018

Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12319

21 January 2018

Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12319

21 January 2018

Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12319

21 January 2018

The efficacy of incretin therapy in patients with type 2 diabetes undergoing hemodialysis

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12319

21 January 2018

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12319

21 January 2018

Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men.

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12319

21 January 2018

Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12319

21 January 2018

Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes: a prospective pilot study

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12319

21 January 2018

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12319

21 January 2018

Decreased insulin secretion and incretin concentrations and increased glucagon concentrations after a high-fat meal when compared with a high-fruit and -fiber meal.

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12319

21 January 2018

Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12319

21 January 2018

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12319

21 January 2018

A protocol for a randomised, double-blind, placebo-controlled study of the effect of LIraglutide on left VEntricular function in chronic heart failure patients with and without type 2 diabetes (The LIVE Study)

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12319

21 January 2018

One-hour postload plasma glucose levels and left ventricular mass in hypertensive patients

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12319

21 January 2018

Hemoglobin A1c variability as an independent correlate of cardiovascular disease in patients with type 2 diabetes: a cross-sectional analysis of the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12319

21 January 2018

Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12319

21 January 2018

Effect of hemodialysis on plasma glucose profile and plasma level of liraglutide in patients with type 2 diabetes mellitus and end-stage renal disease: a pilot study

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12319

21 January 2018

Identifiers

10.1111/1744-9987.12319

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/26556397

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/26556397

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51294221&oldid=1517801771"